SCHEMBL2207388

SCHEMBL2207388

COc1ccc(C(N)=O)c(Nc2nc(Nc3ccc(N4CCOC[C@@H]4C)cc3OC)[nH]c3nccc2-3)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 4/20 0.43
▸ MAPK10 P53779 3/20 0.43
▸ MAPK8 P45983 2/20 0.43
▸ MAPK9 P45984 2/20 0.43
▸ MTOR P42345 5/20 0.39
▸ MAPK3 P27361 1/20 0.38
▸ CHEK1 O14757 3/20 0.37
▸ ATR Q13535 2/20 0.37
▸ PDCD1 Q15116 2/20 0.37
▸ CD274 Q9NZQ7 2/20 0.37
▸ ATRIP Q8WXE1 1/20 0.37
▸ ALK Q9UM73 3/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ PLK4 O00444 1/20 0.36
▸ AURKA O14965 1/20 0.36
▸ DCLK1 O15075 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ DYRK3 O43781 1/20 0.36
▸ JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209128 0.93 IGF1R (0.52) IGF1RMAPK10MAPK8MAPK9MTOR
SCHEMBL2206442 0.91 IGF1R (0.44) IGF1RMAPK10MAPK8MAPK9MTOR
SCHEMBL2205774 0.89 IGF1R (0.46) IGF1RMAPK10MAPK8MAPK9MTOR
SCHEMBL2202791 0.85 IGF1R (0.46) IGF1RMAPK10MAPK8MAPK9MTOR
SCHEMBL2208735 0.85 IGF1R (0.45) IGF1RMAPK10MAPK8MAPK9ALK
SCHEMBL2205134 0.82 IGF1R (0.65) IGF1RMAPK10MAPK8MAPK9CHEK1
SCHEMBL2207865 0.81 MAPK10 (0.65) IGF1RMAPK10MAPK8MAPK9CHEK1
SCHEMBL2202681 0.80 ZAP70 (0.55) IGF1RMAPK10MAPK8MAPK9CHEK1
SCHEMBL12429412 0.79 IGF1R (0.69) IGF1RMAPK10MAPK8ALKINSR
SCHEMBL2205196 0.78 IGF1R (0.60) IGF1RMAPK10MAPK8MAPK9ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188292-B1 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER GLAXOSMITHKLINE IP DEV LTD (GB) 2013-05-29 — — EP disclosed
US-7981903-B2 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer GLAXOSMITHKLINE LLC (US) 2011-07-19 — — US disclosed
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer GLAXOSMITHKLINE LLC 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer IGF1R, IGFBP2, IGFBP1 IGF1R 1/4885MAPK10 1958/4885MAPK8 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback